Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas (Q35419401)

8 August 2017

Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas (English)

1 reference

8 August 2017

1 reference

9

Lauren E Abrey

1 reference

8 August 2017

7

Katherine S Panageas

1 reference

8 August 2017

12

Eric C Holland

1 reference

8 August 2017

Fabio M Iwamoto

1

1 reference

8 August 2017

Andreas F Hottinger

2

1 reference

8 August 2017

Sasan Karimi

3

1 reference

8 August 2017

Elyn Riedel

4

1 reference

8 August 2017

Jocelynn Dantis

5

1 reference

8 August 2017

Maryam Jahdi

6

1 reference

8 August 2017

Andrew B Lassman

8

1 reference

8 August 2017

Martin Fleisher

10

1 reference

8 August 2017

Lisa M DeAngelis

11

1 reference

8 August 2017

Adília Hormigo

13

1 reference

8 August 2017

10 August 2011

1 reference

8 August 2017

1 reference

8 August 2017

13

1 reference

8 August 2017

11

1 reference

8 August 2017

1244-1251

1 reference

A multigene predictor of outcome in glioblastoma.

8 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3199155

YKL-40, a secreted glycoprotein, promotes tumor angiogenesis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3199155

IDH1 and IDH2 mutations in gliomas

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3199155

Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3199155

Response criteria for glioma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3199155

Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and -2.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3199155

Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3199155

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3199155

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3199155

MGMT gene silencing and benefit from temozolomide in glioblastoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3199155

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3199155

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3199155

An overview of methods for the analysis of longitudinal data

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3199155

Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3199155

Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3199155

Plasma YKL-40: a potential new cancer biomarker?

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3199155

Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3199155

End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3199155

YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3199155

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3199155

Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3199155

YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3199155

YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3199155

Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3199155

Early detection and prognosis of ovarian cancer using serum YKL-40.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3199155

Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3199155

Response criteria for phase II studies of supratentorial malignant glioma

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3199155

High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer

26 September 2018

1 reference

12 December 2020

High serum YKL-40 level in patients with small cell lung cancer is related to early death

1 reference

12 December 2020

Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population

1 reference

12 December 2020

High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia

1 reference

12 December 2020

Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma

1 reference

12 December 2020

Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival

1 reference

12 December 2020

Diurnal, Weekly, and Long-Time Variation in Serum Concentrations of YKL-40 in Healthy Subjects

1 reference

12 December 2020

Identifiers

DOI

10.1093/NEUONC/NOR117

1 reference

8 August 2017

1 reference

8 August 2017

1 reference